









Markets
/
Stocks
/
nasdaq-rnac
/

Cartesian Therapeutics Inc

RNAC

10.310USD

+1.160+12.68%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

268.06MMarket Cap

LossP/E TTM



Cartesian Therapeutics Inc

10.310

+1.160+12.68%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

125 / 507

Overall Ranking

246 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

36.429

Target Price

+279.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Growing

The company is in a growing phase, with the latest annual income totaling USD 38.91M.

Undervalued

The company’s latest PE is -13.70, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 22.27M shares, decreasing 5.43% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 496.37K shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 298.00K, representing a year-over-year decrease of 99.11%, while its net profit experienced a year-over-year decrease of 37.70%.

Score

Industry at a Glance

Previous score

6.50

Change



Financials

6.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.06

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.55

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -13.70, which is -99.50% below the recent high of -0.07 and 69.36% above the recent low of -4.20.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 125/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.22, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Cartesian Therapeutics Inc is 40.00, with a high of 42.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.22

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

36.429

Target Price

+298.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Cartesian Therapeutics Inc

RNAC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 10.93 and the support level at 8.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.59

Change

0.41

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.030

Neutral

RSI(14)

48.769

Neutral

STOCH(KDJ)(9,3,3)

40.485

Buy

ATR(14)

0.619

High Vlolatility

CCI(14)

-8.227

Neutral

Williams %R

30.409

Buy

TRIX(12,20)

-0.680

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

9.706

Buy

MA10

9.922

Buy

MA20

10.224

Buy

MA50

11.438

Sell

MA100

10.985

Sell

MA200

14.092

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 85.81%, representing a quarter-over-quarter decrease of 4.73%. The largest institutional shareholder is The Vanguard, holding a total of 496.37K shares, representing 1.91% of shares outstanding, with 14.53% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Springer Timothy A

8.64M

+0.26%

Seven One Eight Three Four Irrevocable Trust

4.56M

Fidelity Management & Research Company LLC

2.34M

-3.44%

Singer (Michael S.)

707.06K

-0.09%

MPM BioImpact LLC

790.78K

+9.66%

TAS Partners, L.L.C.

656.51K

+23.92%

BlackRock Institutional Trust Company, N.A.

608.03K

+0.25%

Invus Public Equities Advisors, LLC

563.27K

-1.57%

Kalayoglu (Murat)

502.42K

-1.74%

The Vanguard Group, Inc.

Star Investors

503.54K

+17.24%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.